This inventor holds 1 USPTO granted patent. Top assignee: Suzhou Galaxy Biopharma, Co., Ltd.. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Chao Bian: Innovator in Monoclonal Antibody Research
Introduction
Chao Bian is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on combating hepatitis C virus (HCV) infections, which pose a serious health threat globally.
Latest Patents
Chao Bian holds a patent for a human monoclonal antibody known as 8D6, which targets HCV infection. This innovative antibody binds to the E2 subunit of the HCV capsid protein, effectively preventing the virus from infecting susceptible host cells. The patent outlines the potential for genetic engineering of various forms of antibodies using the variable region gene or complementary determining region (CDR) gene, allowing for the production of therapeutic antibodies in both prokaryotic and eukaryotic expression systems.
Career Highlights
Chao Bian is currently employed at Suzhou Galaxy Biopharma Co., Ltd., where he continues to advance his research in monoclonal antibodies. His work has the potential to lead to new therapeutic options for individuals affected by HCV, contributing to the ongoing fight against viral infections.
Collaborations
Chao Bian collaborates with notable colleagues, including Honglin Zhou and Jie Liu. Their combined expertise enhances the research efforts at Suzhou Galaxy Biopharma, fostering innovation in the field of biotechnology.
Conclusion
Chao Bian's contributions to the development of monoclonal antibodies represent a significant advancement in the treatment of hepatitis C virus infections. His innovative work continues to pave the way for new therapeutic strategies in the fight against viral diseases.